Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prolight Diagnostics ABNGM:PRLD +2.29%31 EV-to-EBITDA is -3.91 as of Aug. 02, 2026. GuruFocus rates NGM:PRLD with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 512 Medical Devices & Instruments companies, Prolight Diagnostics AB ranks worse than 195312.3% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Prolight Diagnostics AB's enterprise value is kr198.34 Mil.
Prolight Diagnostics AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was kr-50.76 Mil. Therefore, Prolight Diagnostics AB's EV-to-EBITDA for today is -3.91.
The historical rank and industry rank for Prolight Diagnostics AB's EV-to-EBITDA or its related term are showing as below:
NGM:PRLD'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.09 Med: 0 Max: 0
Current: -3.92
NGM:PRLD's EV-to-EBITDA is ranked worse than 100% of 512
companies
in the Medical Devices & Instruments industry
Industry Median: 14.39
vs NGM:PRLD: -3.92
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Prolight Diagnostics AB (NGM:PRLD) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Prolight Diagnostics AB's PE Ratio (TTM) for today is calculated as:
Prolight Diagnostics AB's share price for today is kr17.90.
Prolight Diagnostics AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-4.870.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGM:PRLD vs ISRG, BDX, MDLN: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Prolight Diagnostics AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prolight Diagnostics AB EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Prolight Diagnostics AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Prolight Diagnostics AB's EV-to-EBITDA falls into.
Prolight Diagnostics AB's current Enterprise Value is kr198.34 Mil.
Prolight Diagnostics AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-50.76 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prolight Diagnostics AB (NGM:PRLD) has a EV-to-EBITDA of -3.91 as of Aug. 02, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Prolight Diagnostics AB. According to the industry distribution chart, Prolight Diagnostics AB ranks #999999 out of 512 companies in the Medical Devices & Instruments industry.
Is Prolight Diagnostics AB's EV-to-EBITDA too high?
Prolight Diagnostics AB's current EV-to-EBITDA is -3.91. Based on the distribution chart, Prolight Diagnostics AB ranks #999999 out of 512 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Prolight Diagnostics AB has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Prolight Diagnostics AB's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Prolight Diagnostics AB ranks #999999 out of 512 companies for EV-to-EBITDA. This places Prolight Diagnostics AB in the lower half of its industry. The industry median EV-to-EBITDA is 14.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.39, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Prolight Diagnostics AB. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prolight Diagnostics AB's current EV-to-EBITDA is -3.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prolight Diagnostics AB stock overvalued right now?
Prolight Diagnostics AB (NGM:PRLD) has a current EV-to-EBITDA of -3.91. The current EV-to-EBITDA is -3.91. Prolight Diagnostics AB's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Prolight Diagnostics AB (NGM:PRLD), the current EV-to-EBITDA is -3.91 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prolight Diagnostics AB along with its subsidiaries, develops Point-of-Care (POC) systems, which are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. Its product portfolio includes Psyros, a digital POC technology, and Microflex.
31GF Score
Get the complete analysis for NGM:PRLD
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:PRLD has been successfully added to your 
